Nutlin-3a

For research use only. Not for use in humans.

Catalog No.S8059 Synonyms: (-)-Nutlin-3

36 publications

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Nutlin-3a has been cited by 36 publications

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M3rOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vjWGlEPTB;MD62NVI{PyEQvF2= NHroR|FUSU6JRWK=
H4 NFPvTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;tRVZkUUN3ME2wMlY3OjhizszN MkDiV2FPT0WU
PA-1 NFfOV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHKV4E3UUN3ME2wMlg4ODl4IN88US=> M3X5O3NCVkeHUh?=
NKM-1 MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorvTWM2OD1zLkC0PVMyKM7:TR?= MYfTRW5ITVJ?
NEC8 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHsTWM2OD1zLkKxOVczKM7:TR?= M1jpVXNCVkeHUh?=
EoL-1-cell NWrGc3FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TUZ2lEPTB;MT6yOlcxOSEQvF2= NHz1SZRUSU6JRWK=
K5 NUj1O4pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfBdIVKSzVyPUGuOFIxPzJizszN MV7TRW5ITVJ?
QIMR-WIL NFHqSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvMZlFKSzVyPUGuOlA5PTRizszN MVrTRW5ITVJ?
MOLT-16 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwN{i2NFQh|ryP M2G3bHNCVkeHUh?=
CHP-212 M3;SS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH6epg2UUN3ME2xMlgyOzZ7IN88US=> NV73fnhqW0GQR1XS
CTB-1 NGDIOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwMEKyOFYh|ryP M{[0OHNCVkeHUh?=
MOLT-4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwM{K4OVMh|ryP NIDBV5BUSU6JRWK=
A101D NYHXPWRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XnOGlEPTB;Mj6zOVAyKM7:TR?= M{PqO3NCVkeHUh?=
DOHH-2 M3\XXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwNEKyO|kh|ryP MUPTRW5ITVJ?
ES4 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;3cIFHUUN3ME2yMlQ{OTV3IN88US=> NVyzNZA2W0GQR1XS
SW780 NHjWXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPxfWRKSzVyPUKuOVA5QDNizszN MYTTRW5ITVJ?
VA-ES-BJ NVvx[W5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK4fI1KSzVyPUKuOVQyOSEQvF2= NXuyRYh6W0GQR1XS
RPMI-8866 NE\WZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJwNU[yNVQh|ryP MXjTRW5ITVJ?
ML-2 NFHHOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWzXVJVUUN3ME2yMlU3PTd4IN88US=> NVrRW3VNW0GQR1XS
MSTO-211H M1TuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwNUe0OVEh|ryP MUTTRW5ITVJ?
JVM-3 M4PwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJwNUmzNlQh|ryP MVfTRW5ITVJ?
A3-KAW NFvhU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGexR5NKSzVyPUKuOlE5OThizszN NIWzVmdUSU6JRWK=
DK-MG NY[zNpgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DibGlEPTB;Mj62NlQ4OSEQvF2= MknYV2FPT0WU
LNCaP-Clone-FGC Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH65d5lKSzVyPUKuOlQ{OThizszN NGOxPIVUSU6JRWK=
HT-144 NWH1S482T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJwNkS1O|ch|ryP M1m0NnNCVkeHUh?=
NB69 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJwNkWzN|Qh|ryP M2XRc3NCVkeHUh?=
A172 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jLVGlEPTB;Mj62O|U5QCEQvF2= MWDTRW5ITVJ?
RS4-11 NILyTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJwN{K0NFch|ryP MVrTRW5ITVJ?
DU-4475 M4mwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXLTWM2OD1{Lke5OVAzKM7:TR?= NFP1W3RUSU6JRWK=
SJSA-1 NYfRSmNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvNc45XUUN3ME2yMlgzPTV4IN88US=> MkjkV2FPT0WU
BV-173 MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLJTWM2OD1{Lki0OFM6KM7:TR?= MoXlV2FPT0WU
U-2-OS MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XFTWlEPTB;Mj65NVA4KM7:TR?= MWfTRW5ITVJ?
CHP-134 NETTUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PC[mlEPTB;Mj65N|g5OiEQvF2= M{DVNXNCVkeHUh?=
D-502MG MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjlTWM2OD1{Lkm3NVU1KM7:TR?= NVTUc5o4W0GQR1XS
KS-1 NVXrN4RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu2TWM2OD1|LkCxOlI{KM7:TR?= MoLTV2FPT0WU
A204 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;1WGlEPTB;Mz6wOVU5QCEQvF2= NWHx[phiW0GQR1XS
KGN NE\KS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jv[2lEPTB;Mz6wPFQ6PiEQvF2= MUTTRW5ITVJ?
NCI-H292 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7lb|dKSzVyPUOuNVIxOjhizszN M3LBbXNCVkeHUh?=
CAKI-1 M1rOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\jTWM2OD1|LkGyOlk1KM7:TR?= M1;QbHNCVkeHUh?=
C2BBe1 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS5TWM2OD1|LkG3NFI3KM7:TR?= NX3sdnBUW0GQR1XS
NB10 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjxTphKSzVyPUOuNlA6PjZizszN NXTvPXlKW0GQR1XS
MHH-NB-11 NVn5WIFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jjOmlEPTB;Mz6yOlgzPyEQvF2= NEe3WlJUSU6JRWK=
NCI-SNU-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTJV49MUUN3ME2zMlI4QDR|IN88US=> M2HrZ3NCVkeHUh?=
HCT-116 NF6wb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPQfJRUUUN3ME2zMlMxOzN3IN88US=> MXXTRW5ITVJ?
G-401 NUTrRYloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKwTWM2OD1|LkO2N|IzKM7:TR?= MUnTRW5ITVJ?
MN-60 NHvBO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrWbm5KSzVyPUOuOFQxQTJizszN M1TxfnNCVkeHUh?=
SW982 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3VTWM2OD1|LkWwPFQ5KM7:TR?= M4\UenNCVkeHUh?=
RKO MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rTVGlEPTB;Mz61N|k{PiEQvF2= Mk[5V2FPT0WU
D-283MED MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXRTWM2OD1|LkW3PVg3KM7:TR?= M2XDTXNCVkeHUh?=
LB996-RCC MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW5[|RiUUN3ME2zMlYzPTV6IN88US=> NX62fopLW0GQR1XS
A549 NFjueHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M323e2lEPTB;Mz62N|U2OiEQvF2= NWfObnpGW0GQR1XS
LB2241-RCC M3W5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2mxOWlEPTB;Mz62OVcxQCEQvF2= NHPkfIZUSU6JRWK=
SK-HEP-1 NV7rcJVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf4ToNKSzVyPUOuO|QzQTdizszN NF\WU|dUSU6JRWK=
G-402 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;XOIRHUUN3ME2zMlgxQDN{IN88US=> M2DwOXNCVkeHUh?=
GOTO MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNwOESzN|Mh|ryP M{eybHNCVkeHUh?=
LOXIMVI NFzlNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomxTWM2OD1|Lki1Olc2KM7:TR?= NF3MOmZUSU6JRWK=
NH-12 NGTzOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLYTWM2OD12LkCxPVU6KM7:TR?= MWHTRW5ITVJ?
CTV-1 M{fFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTRwMEe5O|Mh|ryP NVnCSotCW0GQR1XS
CP50-MEL-B NXflZmFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WzcmlEPTB;ND6yOFM6OiEQvF2= M{DNd3NCVkeHUh?=
RH-18 M2DVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRwMke3NFYh|ryP NV3pW3o6W0GQR1XS
NB17 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTRwM{G3Olgh|ryP MmnrV2FPT0WU
A375 M{LFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XCPWlEPTB;ND6zN|UzPCEQvF2= NYj4U2wzW0GQR1XS
IST-MES1 NXfj[ZRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4riRmlEPTB;ND60NVQyOSEQvF2= M4PlbnNCVkeHUh?=
MZ2-MEL NHPEd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT4OXRKSzVyPUSuOVAyPTVizszN MYDTRW5ITVJ?
CAL-54 NE[1OGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrTUFBKSzVyPUSuOVMxOTlizszN NH\mU4dUSU6JRWK=
NCI-H28 M2XvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TE[WlEPTB;ND62NlcyPyEQvF2= M1X3NHNCVkeHUh?=
D-247MG NIXmRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL0TWM2OD12Lke1NFczKM7:TR?= MWDTRW5ITVJ?
NCI-H460 M3n1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTRwOUGxNlch|ryP MV3TRW5ITVJ?
MCF7 NXzN[pM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXGTWM2OD13LkS0NlQ1KM7:TR?= M1;LXHNCVkeHUh?=
697 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL6NGpIUUN3ME21MlQ1PTVizszN MUDTRW5ITVJ?
ONS-76 NF36S|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIizWJpKSzVyPUWuOVcxODlizszN NX\IRo9xW0GQR1XS
C32 NW\uUIF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTVwNkCwNlkh|ryP MlvKV2FPT0WU
OS-RC-2 NXLNcHQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz6[W9PUUN3ME21Mlc{QDh5IN88US=> MmPrV2FPT0WU
MEL-HO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrnSmxmUUN3ME21Mlg2PjZ5IN88US=> MVHTRW5ITVJ?
LoVo MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZwMEG2NlQh|ryP NWTIOoVDW0GQR1XS
AGS M4W0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\KO4tKSzVyPU[uNVQ5OjhizszN M4LwXHNCVkeHUh?=
GI-ME-N NUP3OVJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;QZmlEPTB;Nj6yNlQzOSEQvF2= MX;TRW5ITVJ?
H-EMC-SS NX3CUVRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH4WXNKSzVyPU[uN|g3KM7:TR?= MmD4V2FPT0WU
RVH-421 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTZwNEK0Nlgh|ryP NWnwflNyW0GQR1XS
SW954 MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXwTWM2OD14LkW1OVczKM7:TR?= MUjTRW5ITVJ?
NB5 MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7jV2hKSzVyPU[uOVYyQDNizszN MVnTRW5ITVJ?
NCI-H2122 M1rSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTZwNUi3PVMh|ryP NXjCbYl3W0GQR1XS
AM-38 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPPfVJKSzVyPU[uO|U3OzlizszN MnrTV2FPT0WU
KNS-81-FD M321Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTZwN{[0PVQh|ryP M3H4fHNCVkeHUh?=
LS-513 M4\Yc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrJO5hKSzVyPU[uO|kxOjZizszN Mmf6V2FPT0WU
A427 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTZwOEe4Nlkh|ryP M3HacnNCVkeHUh?=
WM-115 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTZwOUOyN{DPxE1? M{nHWnNCVkeHUh?=
COLO-829 MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LzTmlEPTB;Nz6yOFE5QCEQvF2= MnuyV2FPT0WU
NCI-H1650 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDqTWM2OD15LkO5NlI5KM7:TR?= MnP3V2FPT0WU
NCI-H358 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\xOWRKSzVyPUeuOFQ5PzlizszN MUDTRW5ITVJ?
HT-1080 MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rPSWlEPTB;Nz60PFI2PCEQvF2= M3v1R3NCVkeHUh?=
HCC2218 Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzKcohKSzVyPUeuOlI6PyEQvF2= MlnlV2FPT0WU
NCI-H661 NVXvSFF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1znZmlEPTB;Nz64O|A3QSEQvF2= MV7TRW5ITVJ?
KM-H2 M{n2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{exbGlEPTB;Nz64PFY6PCEQvF2= MUnTRW5ITVJ?
RPMI-2650 M3S3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG3TWM2OD15Lkm0OFE1KM7:TR?= M1W5S3NCVkeHUh?=
NCI-H226 NVjXcZozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;F[GZKSzVyPUiuNlEyOjJizszN MlT4V2FPT0WU
MKN45 M2ixfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXKTWM2OD16LkK2OlAzKM7:TR?= NH:wWFJUSU6JRWK=
D-392MG NEfHb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[wXWRKSzVyPUiuOVI4OjJizszN NV31cGNXW0GQR1XS
RCC10RGB NGCzWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHzSGhKSzVyPUiuPFY3QTVizszN NVWyWpNlW0GQR1XS
CAL-51 M2HTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17z[WlEPTB;OT6xNFI2OSEQvF2= NULnRmRUW0GQR1XS
COLO-678 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHRTWM2OD17LkOyPFEyKM7:TR?= MnjUV2FPT0WU
SK-MEL-24 MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\i[lRQUUN3ME25MlU2QDV4IN88US=> MkXGV2FPT0WU
SK-MEL-30 NVrWSmRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTlwOUS0O|Yh|ryP NXLLNm05W0GQR1XS
MMAC-SF NUP6clhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFyLkO5OlEh|ryP NGP0SIZUSU6JRWK=
NTERA-S-cl-D1 MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTVTWM2OD1zMD62OVA5KM7:TR?= NYPPWGt1W0GQR1XS
NB12 NHXOVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfIUYhKSzVyPUGxMlUxOyEQvF2= MYLTRW5ITVJ?
UACC-257 NWPpbVlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPRWFZKSzVyPUGxMlg3QTVizszN MX\TRW5ITVJ?
LAN-6 M2LCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvrZXJ4UUN3ME2xNU46QTJ6IN88US=> NELXVoxUSU6JRWK=
SW1573 M4jRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HCXGlEPTB;MUKuN|A5PiEQvF2= NWnPSGpuW0GQR1XS
NMC-G1 NYfHW41tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnSTWM2OD1zMj60NVc2KM7:TR?= NWTXZnVEW0GQR1XS
SHP-77 NWrEeWFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL4TWM2OD1zMj61OVc1KM7:TR?= NYnqOGNXW0GQR1XS
IGROV-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz2PVFoUUN3ME2xNk43PTd|IN88US=> NYTMXXZMW0GQR1XS
22RV1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF{LkiwOVkh|ryP NEfxbmFUSU6JRWK=
SK-MEL-3 NH3TXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq0XZNKSzVyPUGzMlM6PzNizszN M1n4PXNCVkeHUh?=
NCI-H1563 Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDNTWM2OD1zMz60NlAzKM7:TR?= M1;5VnNCVkeHUh?=
IGR-1 NUe4fYFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvKNVFFUUN3ME2xOE4xOzR5IN88US=> MWDTRW5ITVJ?
EW-3 NYPWOWx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWzWHhKSzVyPUG0MlE3OzlizszN NYXyXnRQW0GQR1XS
JEG-3 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1qxTGlEPTB;MUSuOFk2OyEQvF2= NEPqSmtUSU6JRWK=
ES3 NVO2TVg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK4bFdvUUN3ME2xOE43PTZ{IN88US=> NHTPfoZUSU6JRWK=
MDA-MB-175-VII M3z4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPZTWM2OD1zND63NVEyKM7:TR?= NX[wXlBZW0GQR1XS
P30-OHK MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF3LkC0PVYh|ryP NGfJVIpUSU6JRWK=
GP5d NX6xfZU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjxelhKSzVyPUG1MlE1PjZizszN NXPiOWZHW0GQR1XS
HMV-II M2\Ocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF3LkOzN|Mh|ryP NHzZXnRUSU6JRWK=
COLO-679 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\0NoZKSzVyPUG1MlUxOSEQvF2= Mn74V2FPT0WU
JAR M2rzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjDZ21KSzVyPUG1MlczODVizszN MVfTRW5ITVJ?
NCI-H1666 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF3LkmzPVkh|ryP M2nIXXNCVkeHUh?=
SW48 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXGTWM2OD1zNT65OVE3KM7:TR?= Mn7HV2FPT0WU
NCI-H720 MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETGO|FKSzVyPUG1Mlk6QDlizszN NILhO|dUSU6JRWK=
HT-1197 NUHKW4huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:yN2lEPTB;MU[uNFM2OiEQvF2= M1vnfHNCVkeHUh?=
HL-60 Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TKO2lEPTB;MU[uNFM5PCEQvF2= MlPiV2FPT0WU
BEN NWToeJN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf6TWM2OD1zNj61OlM5KM7:TR?= NUS4ZlI5W0GQR1XS
HAL-01 M1LxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfuTGJKSzVyPUG2Mlg6ODlizszN NW\SNJhRW0GQR1XS
SW900 NVjkXHNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;1TGdKSzVyPUG2MlkyOzJizszN MVLTRW5ITVJ?
SBC-1 NUH1bZJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f0cmlEPTB;MUeuOVQzQSEQvF2= MlXLV2FPT0WU
SH-4 NGjrUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj0V2tKSzVyPUG3MlU5PDFizszN NF71XXlUSU6JRWK=
UACC-62 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7CeItKSzVyPUG3Mlc3OzdizszN M1\jUHNCVkeHUh?=
BHT-101 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj0TWM2OD1zOT64O|A2KM7:TR?= Mm\HV2FPT0WU
DB M{Tl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJzLkW2OFkh|ryP MWDTRW5ITVJ?
SK-MEL-1 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS5Z5NKSzVyPUKxMlU5PzJizszN MYjTRW5ITVJ?
NCI-H747 M4f6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[4eWlEPTB;MkKuO|M4QSEQvF2= NVm2ZpVjW0GQR1XS
SK-LU-1 NH\y[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDWXlc5UUN3ME2yN{4{PTJ2IN88US=> NH:4WYZUSU6JRWK=
KG-1 NUL1dmFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ|LkS5OFYh|ryP NHPBcHlUSU6JRWK=
LXF-289 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnLS4VKSzVyPUKzMlcyPCEQvF2= NWX0O|U5W0GQR1XS
HCC1954 NYHGVY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPpbmRKSzVyPUK0Mlg5PDRizszN NX;LdHprW0GQR1XS
Ramos-2G6-4C10 NEW1NXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW5ZXJKSzVyPUK2MlQ6QDFizszN MY\TRW5ITVJ?
DBTRG-05MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLYcY0zUUN3ME2yOk43PDh6IN88US=> MX7TRW5ITVJ?
NCI-H2052 NGrMVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPzTWM2OD1{Nz61Olg1KM7:TR?= Mli0V2FPT0WU
RMG-I MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrsTWM2OD1{OT60NVM6KM7:TR?= MX;TRW5ITVJ?
H9 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG2Vmp{UUN3ME2zNU4{ODB6IN88US=> NIXKc2FUSU6JRWK=
GR-ST MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr3WllKSzVyPUOyMlQ1PTNizszN NFnmTYRUSU6JRWK=
Mo-T M3vGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\sTWM2OD1|Mj61NFQ3KM7:TR?= Mk\JV2FPT0WU
SW1088 M{nDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nQVGlEPTB;M{KuPVgxOSEQvF2= NHrXNYNUSU6JRWK=
LB2518-MEL NInmTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX4TWM2OD1|Mz6wO|k4KM7:TR?= NHj2b2VUSU6JRWK=
NCI-H82 M4PhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzRWIZCUUN3ME2zN{4yPjZzIN88US=> MYXTRW5ITVJ?
LAMA-84 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M376ZWlEPTB;M{SuOlA4OyEQvF2= M{HU[3NCVkeHUh?=
KYSE-450 MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnZcJp{UUN3ME2zOE43Pzd4IN88US=> MUPTRW5ITVJ?
LU-99A MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTN3LkCwNFch|ryP NV30XmFiW0GQR1XS
BE-13 NHzzfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjYTWM2OD1|NT62OVQ2KM7:TR?= NF:5cXFUSU6JRWK=
GAK MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkCyTWM2OD1|NT62PVUh|ryP MVPTRW5ITVJ?
NCI-H1573 Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTN3Lki4NVgh|ryP NXe5VVR2W0GQR1XS
AsPC-1 NH\Hb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG5O3R4UUN3ME2zOk4yPTJ5IN88US=> NVrKSmNyW0GQR1XS
HDLM-2 NYn3S5lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M134ZmlEPTB;M{[uN|E3KM7:TR?= MUDTRW5ITVJ?
NCI-H441 NW[5OHZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\qUWxKSzVyPUO3MlA3QTFizszN M{fLVnNCVkeHUh?=
CAL-27 M{T1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfuTIpqUUN3ME2zO{44OjNzIN88US=> MmPiV2FPT0WU
OVCAR-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CzeWlEPTB;M{muN|E5OSEQvF2= MorXV2FPT0WU
RPMI-8226 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTN7LkW5PEDPxE1? MWPTRW5ITVJ?
EFO-21 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTRyLkW4NVQh|ryP NG\RPI5USU6JRWK=
SNU-C2B NHuzVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTRzLkWwPFQh|ryP MVnTRW5ITVJ?
VM-CUB-1 NGG4UIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\JV2ZSUUN3ME20N{45ODN5IN88US=> NIjBXVVUSU6JRWK=
NCI-H2087 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonuTWM2OD12NT6wNlM{KM7:TR?= MUXTRW5ITVJ?
EW-16 MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR4LkOxN|ch|ryP NF\Fb3lUSU6JRWK=
SK-N-AS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\4VFVKSzVyPUS2MlcyPjdizszN MmHVV2FPT0WU
COR-L105 NHXqO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PnO2lEPTB;NE[uPFg2PyEQvF2= NHfN[oxUSU6JRWK=
DEL NHGwTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDzZ2VLUUN3ME20PE4xPDJ7IN88US=> MmT2V2FPT0WU
JVM-2 MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M120[WlEPTB;NEiuNFU2QCEQvF2= MWTTRW5ITVJ?
KARPAS-45 M2TQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTR7LkS1N|gh|ryP NXvDOZRHW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase; 

PubMed: 16014563     


Expression of apoptosis- and cell-cycle–associated proteins in OCI-AML-3 cells, which were treated with 5 μM Nutlin-3a for the indicated times. Nutlin-3a induced increased protein expression of p53, MDM2, and p21 in OCI-AML-3 cells in a time-dependent fashion. Nutlin-3a induced Noxa, a BH3-only member of the Bcl-2 family, followed by caspase activation. β-actin was used to confirm equal loading of proteins. Arrowheads indicate cleared caspases.

BMI-1; 

PubMed: 26887044     


Western blot analysis of BMI-1 and actin was performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after 24 hours treatment with increasing concentrations of Nutlin-3a (1 μM, 2 μM, 5 μM) and with DMSO control. 

p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70; 

PubMed: 23666059     


Expression of the indicated proteins in whole-cell lysates of cells treated for 96 h with 50 μM resveratrol (R), 5 μM nutlin-3a (N), or co-treated with both substances (RN).

16014563 26887044 23666059
Immunofluorescence
p-p21 / β-actin; 

PubMed: 31083332     


Cells were treated with fluoride (5 mM) with/without Nutlin-3a for 24 h. p-p21 (green), nucleus (DAPI; blue) and β-actin (red) expression were detected by immunocytochemistry. Nutlin-3a addition augmented p-p21 expression compared to NaF treatment alone.

P53; 

PubMed: 21394100     


At 12 h following treatment with nutlin-3a, DoHH2 and MCA cells had increased levels of p53 visualized by immunofluorescence. p53 localization was predominantly nuclear. The 4',6-diamidino-2-phenylindole was used as counterstain of the nuclei.

Ac-p300; 

PubMed: 30240745     


HepG2 cells were treated with 5 μM Nutlin-3a for 24 hr, and the levels of Ac-p300 and p53 were assessed by co-immunofluorescence. Fluorescence intensity of Ac-p300 in control cells versus Nutlin-3a-treated cells have been quantified (represented as mean ± SD, unpaired two-tailed Student's t test, n = 50 of three independent experiments). Scale bar, 10 μm.

31083332 21394100 30240745
Growth inhibition assay
Cell viability; 

PubMed: 26248031     


All 15 cell lines were plated in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.

26248031
In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
- Collapse

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
- Collapse
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID